STOCK TITAN

Zai Lab Limited Stock Price, News & Analysis

ZLAB Nasdaq

Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.

Zai Lab Limited (ZLAB) is a global biopharmaceutical innovator developing therapies for oncology, autoimmune disorders, and infectious diseases. This news hub provides verified updates on clinical advancements, regulatory milestones, and strategic partnerships critical to investors and healthcare professionals.

Access official press releases and curated news covering clinical trial results, regulatory submissions, collaboration announcements, and financial disclosures. Monitor ZLAB's progress in combining proprietary research with in-licensed therapies through a centralized, reliable source.

Stay informed about pipeline developments and global operations with factual reporting that emphasizes scientific rigor and regulatory expertise. This resource eliminates speculation while highlighting initiatives directly impacting patient care and market positioning.

Bookmark this page for efficient tracking of ZLAB's advancements. Return regularly for authoritative updates on therapeutic innovations addressing complex medical challenges worldwide.

Rhea-AI Summary

Zai Lab announced that China’s NMPA has approved AUGTYRO™ (repotrectinib) for treating ROS1-positive NSCLC based on the TRIDENT-1 trial, showing high response rates and durable responses. The drug addresses an unmet need for patients with treatment options due to resistance. The study demonstrated promising results, positioning repotrectinib as a potential new standard of care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.17%
Tags
none
-
Rhea-AI Summary

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) reported a strong first quarter of 2024 with net product revenue of $87.1 million, a 39% year-over-year growth. The company highlighted VYVGART® sales of $13.2 million, regulatory reviews ongoing for several products, and a robust balance sheet with $750.8 million in cash. With plans for new launches in 2024 and a focus on profitability by 2025, Zai Lab is poised for significant growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.8%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences clinical trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
none

FAQ

What is the current stock price of Zai Lab (ZLAB)?

The current stock price of Zai Lab (ZLAB) is $32.73 as of July 11, 2025.

What is the market cap of Zai Lab (ZLAB)?

The market cap of Zai Lab (ZLAB) is approximately 4.0B.
Zai Lab Limited

Nasdaq:ZLAB

ZLAB Rankings

ZLAB Stock Data

4.02B
106.54M
1.47%
53.9%
7.23%
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI